Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

05 Oct 2022

Mary O’Brien, Luis Paz-Ares, Sandrine Marreaud, Urania Dafni, Kersti Oselin, Libor Havel, Emilio Esteban, Dolores Isla, Alex Martinez-Marti, Martin Faehling, Masahiro Tsuboi, Jong-Seok Lee, Kazuhiko Nakagawa, Jing Yang, Ayman Samkari, Steven M Keller, Murielle Mauer, Nitish Jha, Rolf Stahel, Benjamin Besse, Solange Peters, EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 Investigators

The Lancet Oncology, 2022 Oct.

Abstract link

Forse può anche interessarti